Screening for Alzheimer’s disease Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine.

Slides:



Advertisements
Similar presentations
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.
Advertisements

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.
The Brief Cognitive Assessment Tool (BCAT): A New Test Emphasizing Contextual Memory and Executive Functions Drs. William Mansbach, Elizabeth MacDougall,
Epidemiological study of mild cognitive impairment and pilot evaluation of methods of early dementia detection in Chinese community Yueqin Huang MD MPH.
MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
Brief Cognitive Assessment Tool (BCAT®) Training Program
Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.
Introduction to Biostatistics, Harvard Extension School © Scott Evans, Ph.D.1 Evaluation of Screening and Diagnostic Tests.
CHAPTER SIX Interpretation of Clinical Test Data Posttest probability of disease is determined by pretest probability and the probability of the test providing.
Signed Paired Associates Test (SPAT). SPAT Structure Similar to WMS “paired associates” subtest 14 sign pairs – 7 easy & 7 hard Based on sign associate.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
The New Brief Cognitive Assessment Tool (BCAT): The Role of Cognitive Assessment in Improving Health Outcomes Dr. William Mansbach October 25, 2011.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Dementia with Lewy Bodies
ACT on Alzheimer’s Disease Curriculum Module VI: Screening.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Screening and Early Detection Epidemiological Basis for Disease Control – Fall 2001 Joel L. Weissfeld, M.D. M.P.H.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Statistics in Screening/Diagnosis
BASIC STATISTICS: AN OXYMORON? (With a little EPI thrown in…) URVASHI VAID MD, MS AUG 2012.
Multiple Choice Questions for discussion
UOG Journal Club: January 2013
Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 21, 2010.
Diagnostic Cases. Goals & Objectives Highlight Bayesian and Boolean processes used in classic diagnosis Demonstrate use/misuse of tests for screening.
VAMC/ST LOUIS UNIVERSITY
MEMORY ASSESSMENT in the LAB vs. the CLINIC
Chapter 6 Memory.
Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.
BY DR ZAINAB ABDULZAEEZ UMAR DEPARTMENT OF FAMILY MEDICINE AMINU KANO TEACHING HOSPITAL.
Detecting Individual Differences in Changes in Memory Functioning Dr. Len Lecci Professor of Psychology University of North Carolina Wilmington Director.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.
Medio temporal lobe atrophy Lateral Temporal lobe atrophy
Evaluating Results of Learning Blaž Zupan
Screening of diseases Dr Zhian S Ramzi Screening 1 Dr. Zhian S Ramzi.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.
The Diagnostic Process A BRIEF OVERVIEW diagnostic process What is it? to figure out to problem solve method scheme.
Reliability and Validity of the Intensive Care Delirium Screening Checklist in Turkish Gulsah Kose, Abdullah Bolu, Leyla Ozdemir, Cengizhan Acikel, Sevgi.
10 May Understanding diagnostic tests Evan Sergeant AusVet Animal Health Services.
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Pre-Symptomatic Memory Impairment Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine
AREA OF STUDY 2 MEMORY UNIT 3 THE CONSCIOUS SELF.
Mild Cognitive Impairment (MCI) Screening Tools for Primary Care Providers Jamila Hussain, PGY-3 Faculty Development Cook County-Loyola-Provident Family.
Cognitive Testing, Statistics and Dementia Ralph J. Kiernan Ph.D. 14 th May 2013.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Critical Appraisal Course for Emergency Medicine Trainees Module 5 Evaluation of a Diagnostic Test.
All Hands Meeting 2004 Ontologies for Data Mediation Christine Fennema-Notestine, Ph.D.
Aka STEEL VALLEY SENIORS SURVEY (SVSS)
External multicentric validation of a COPD detection questionnaire.
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
M. Lee Chambliss MD MSPH Associate Professor
Joe Verghese, MBBS, MS. Translating Insights from
Class session 7 Screening, validity, reliability
Evaluating Results of Learning
Brief Visuospatial Memory Test- Revised™ (BVMT-R™) Ralph H
How do we delay disease progress once it has started?
Best Practices to Simplify and Optimize
Memory.
چون آن مرغی که درهر برگ گل نقش خزان بیند
New FDA Guidance on Early Alzheimer’s Disease
New Face-Name Paradigm for Patients with Mild Alzheimer’s Disease
Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.
—ROC curves for each simple test compared with NCS (gold standard) plotting the sensitivity versus 1-specificity (the false-positive rate) for different.
Evidence Based Diagnosis
Presentation transcript:

Screening for Alzheimer’s disease Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine

Is screening needed to improve detection of Alzheimer’s disease ? “…nearly 75% of patients with moderate to severe dementia are unrecognized by primary care clinicians…” (Gifford & Cummings, Neurology,1999) “90% of generalists determine diagnosis of dementia by clinical impression, and 82% are confident about their recognition of mild dementia” (Swearer, Lester, Boudreau & Drachman, American Neurological Association, 2002)

Screening is needed to improve detection of Alzheimer’s disease we need a simple, rapid, accurate screening test with good sensitivity and good specificity that can be used by primary care clinicians to screen everyone at risk an efficient screen for AD must be easy to administer, interpret, and repeat, so that everyone at risk can be screened regularly

Screening Tests Screening tests are not diagnostic tests Screening tests select persons for diagnostic testing Screen everyone at risk, without “pre-screening” Repeat screening if risk persists or increases

Screening for Alzheimer’s disease by screening for memory impairment Memory impairment is required for diagnosis Memory impairment is usually the earliest sign Screening for memory impairment is necessary Effective screening for Alzheimer’s disease requires an efficient screening test for memory impairment with good specificity as well as good sensitivity

Sensitivity and Specificity DISEASE * NO DISEASE * 100 % 80 % 60 % 40 % 20 % SENSITIVITY SPECIFICITY * according to the “Gold Standard”

Screening for memory impairment Sensitivity is necessary to detect impairment Specificity is necessary for ethical, efficient (ppv) screening Maximum recall is needed to detect memory impairment because impairment means that maximum recall has decreased Controlled Learning and Controlled Recall are needed to elicit maximum recall by inducing encoding specificity, ensure that decreased recall is due to impaired memory

Memory Impairment Screen (MIS) *  Controlled Learning brief delay..  Free Recall  Cued Recall * Buschke, et al., Neurology,1999

Controlled Learning

 assures attention and equal processing of all items  induces deep semantic processing  shows that individuals can identify items by their cues  induces all individuals to do the same processing  shows that the required processing was done  ensures that decreased recall is due to impaired memory  induces “Encoding Specificity” to maximize recall

Free Recall *

Category Cued Recall * * only for items not retrieved by free recall

Encoding Specificity “specific encoding operations performed on what is perceived determine what is stored and what is stored determines what retrieval cues are effective in providing access to what is stored” Tulving & Thomson, Psych Review, 1973, page 369 Encoding and retrieval must be coordinated.

Encoding Specificity “…. the probability of retrieval varies directly with the compatibility of the trace and the cue, or the stored information and the retrieval information.” Tulving, Elements of Episodic Memory, page 249 (1985) Encoding and retrieval must be coordinated.

Encoding Specificity retrieval depends on cues effectiveness of cues depends on what was stored what was stored depends on encoding operations performed on what was perceived to maximize retrieval, acquisition & retrieval must be coordinated by controlled learning & retrieval: retrieval cues must be present at encoding

Controlled Learning + Controlled Recall coordinates encoding and retrieval by using the same cues for learning and retrieval induces encoding specificity which improves retrieval and discrimination of dementia because retrieval by aged without dementia is improved more than retrieval by aged with dementia

Recall with and without encoding specificity * * Buschke, Sliwinski, Kuslansky, Lipton, Neurology, 1997

MIS screening for dementia * Buschke, et al., Neurology, 1999

Alternate Forms Reliability Two forms administered to 429 individuals at beginning and end of neuropsychological evaluation Intra-class correlation = 0.69 Coefficient Alpha = 0.67 for each form

Dementia ROC curve =.94

Alzheimer ROC curve =.97

Dementia Discrimination

Alzheimer Discrimination

MIS versus 3-Word Recall * * Kuslansky, Buschke, Katz, Sliwinski, Lipton, JAGS, 2002

3-Word Free Recall

MIS Free Recall

MIS Free and Cued Recall

MIS and 3-Word ROC curves Word MIS True Positives (Sensitivity) False Positives (1 − Specificity) =.78 =.92

Barcelona MIS

Madrid ROC curve Dementia vs No Dementia Spanish-MIS Spanish-MMSE

BRAAKBRAAK MIS r = –.622 p =.003 Normal 6 Path Aging 3 AD 5 VaD 5 FTD 1 DLB 1 MIS correlates with Braak stage * * Verghese, Buschke, Dickson, Kuslansky, Katz, Weidenheim, Lipton, JAGS, 2003

Screening Tests are Not Diagnostic Tests! Screening tests are not diagnostic tests Screening tests select persons for diagnostic testing Everyone at risk should be screened Diagnostic testing is required when screening is positive

MIS Summary  Screening for dementia depends on detection of memory impairment with good specificity and positive predictive value as well as good sensitivity  Screening requires controlled learning, controlled recall, and encoding specificity to elicit maximum retrieval by effective cued recall  MIS improves screening by controlled learning and controlled recall, to maximize recall and optimize sensitivity, specificity, positive predictive value  MIS is a simple, rapid, effective, easily administered screening test with good specificity as well as good sensitivity for Alzheimer’s disease  MIS is recommended by the American Academy of Neurology as a screen for AD